1. Metabolite Profile of Cucurbitane-Type Triterpenoids of Bitter Melon (Fruit of Momordica charantia) and Their Inhibitory Activity against Protein Tyrosine Phosphatases Relevant to Insulin Resistance
- Author
-
Jiyun Baek, Ki Sung Kang, Sunyoung Yoon, Sang J. Chung, Ki Hyun Kim, Jae Sik Yu, Sung Jin Kim, Heesun Kang, and Yong Hoon Lee
- Subjects
0106 biological sciences ,Circular dichroism ,Chromatography ,Momordica ,biology ,Electrospray ionization ,Metabolite ,010401 analytical chemistry ,General Chemistry ,Protein tyrosine phosphatase ,biology.organism_classification ,Mass spectrometry ,Cucurbitane ,01 natural sciences ,0104 chemical sciences ,chemistry.chemical_compound ,chemistry ,General Agricultural and Biological Sciences ,Two-dimensional nuclear magnetic resonance spectroscopy ,010606 plant biology & botany - Abstract
Qualitative analysis of cucurbitane-type triterpenoids of bitter melon (fruit of Momordica charantia L.) using ultraperformance liquid chromatography quadrupole time-of-flight mass spectrometry revealed 27 promising cucurbitane-type triterpenoids, and LC/MS-guided chemical analysis of M. charantia fruit extract led to the isolation and structural characterization of 22 cucurbitane-type triterpenoids (1-22), including 8 new cucurbitane-type triterpenoidal saponins, yeojoosides A-H (1-8). The structures of the new compounds (1-8) were elucidated by spectroscopic methods, including 1D and 2D NMR and high-resolution electrospray ionization mass spectrometry. Their absolute configurations were assigned by quantum chemical electronic circular dichroism calculations, chemical reactions, and DP4+ analysis using gauge-including atomic orbital NMR chemical shift calculations. All isolated compounds (1-22) were examined for inhibitory activity against protein tyrosine phosphatases relevant to insulin resistance. Nine compounds (7, 8, 9, 11, 14, 15, 19, 20, and 21) showed selective inhibitory effects of over 70% against PTPN2. The present results suggested that these compounds would be potential antidiabetic agents.
- Published
- 2021
- Full Text
- View/download PDF